Literature DB >> 14558100

Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase.

Yousuke Murakami1, Tohru Akahoshi, Izumi Hayashi, Hirahito Endo, Atsushi Hashimoto, Shizuka Kono, Hirobumi Kondo, Shinichi Kawai, Matsuhisa Inoue, Hidero Kitasato.   

Abstract

OBJECTIVE: Hematopoietic prostaglandin D synthase (H-PGDS) is a key enzyme in the production of prostaglandin D and its J series metabolites. We evaluated the antiinflammatory effect of retrovirally transfected H-PGDS in order to investigate the role of H-PGDS in monosodium urate monohydrate (MSU) crystal-induced acute inflammation.
METHODS: Expression of endogenous PGDS in a murine air-pouch model of MSU crystal-induced acute inflammation was determined by real-time polymerase chain reaction. H-PGDS complementary DNA (cDNA) was retrovirally transfected into C57BL/6J fibroblasts, and the cells were designated as C57-PGDS cells. Production of prostaglandins by C57-PGDS cells was measured by enzyme immunoassay. The effect of C57-PGDS cells on crystal-induced inflammation was investigated.
RESULTS: Injection of the crystals caused a rapid decrease in H-PGDS expression by infiltrating cells and by the soft tissues around the air pouches. In contrast, expression of interleukin-1beta (IL-1beta) and macrophage inflammatory protein 2 (MIP-2) as well as cellular infiltration were significantly increased during the early stage of inflammation. C57-PGDS cells, but not control cells, produced an increased amount of PGD(2) in vitro, but suppressed production of PGE(2). Injection of C57-PGDS cells into air pouches inhibited cellular infiltration and MIP-2 and IL-1beta expression.
CONCLUSION: In this murine air-pouch model of MSU crystal-induced inflammation, retrovirally transfected H-PGDS cDNA could reduce cellular infiltration, at least partly by inhibiting MIP-2 and IL-1beta. These findings suggest that gene therapy with H-PGDS may be useful for treating inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14558100     DOI: 10.1002/art.11271

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D2.

Authors:  Kyun Ha Kim; Ruxana T Sadikot; Lei Xiao; John W Christman; Michael L Freeman; Jefferson Y Chan; Yu-Kyoung Oh; Timothy S Blackwell; Myungsoo Joo
Journal:  Free Radic Biol Med       Date:  2013-09-09       Impact factor: 7.376

2.  Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.

Authors:  D McGonagle; A L Tan; S Shankaranarayana; J Madden; P Emery; M F McDermott
Journal:  Ann Rheum Dis       Date:  2007-12       Impact factor: 19.103

3.  The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes.

Authors:  Nolan K Maier; Stephen H Leppla; Mahtab Moayeri
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

4.  MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.

Authors:  Chun-Jen Chen; Yan Shi; Arron Hearn; Kate Fitzgerald; Douglas Golenbock; George Reed; Shizuo Akira; Kenneth L Rock
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

5.  Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.

Authors:  Yasunori Kageyama; Eiji Torikai; Akira Nagano
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

6.  A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout.

Authors:  Daniela Marotto; Antonella De Santis; Donatella Chessa; Davide Firinu; Stefano Del Giacco
Journal:  Rheumatol Ther       Date:  2018-03-09

7.  Lipopolysaccharide-dependent interaction between PU.1 and c-Jun determines production of lipocalin-type prostaglandin D synthase and prostaglandin D2 in macrophages.

Authors:  Myungsoo Joo; Minjae Kwon; Yong-Jig Cho; Ningning Hu; Tetyana V Pedchenko; Ruxana T Sadikot; Timothy S Blackwell; John W Christman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-01-30       Impact factor: 5.464

Review 8.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 9.  Mechanisms of spontaneous resolution of acute gouty inflammation.

Authors:  Stefanie Steiger; Jacquie L Harper
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

Review 10.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.